Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.34 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2488623 | 0.83 | CA2 (0.33) | CA2CA1CA9 | |
| SCHEMBL17491120 | 0.81 | CA1 (0.41) | CA2CA1CA9POLBTDP1 | |
| SCHEMBL76110 | 0.78 | CA2 (0.42) | CA2CA1 | |
| SCHEMBL19348714 | 0.77 | CA1 (0.60) | CA2CA1CA9MEN1KMT2A | |
| SCHEMBL1979109 | 0.77 | ALDH1A1 (0.37) | CA2CA1CA9POLBMEN1 | |
| SCHEMBL17466437 | 0.77 | CA1 (0.33) | CA2CA1CA9POLBTDP1 | |
| SCHEMBL7257180 | 0.77 | ALDH1A1 (0.35) | CA2CA1CA9POLBMEN1 | |
| SCHEMBL17456472 | 0.76 | MEN1 (0.35) | CA2CA1CA9MEN1KMT2A | |
| SCHEMBL17456443 | 0.76 | CA1 (0.32) | CA2CA1CA9POLBTDP1 | |
| SCHEMBL17456469 | 0.76 | CA1 (0.32) | CA2CA1CA9POLBTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 274 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10633357-B2 | Intermediates and process for preparing intermediates in the production of substituted pyrazolopyridines | ADVERIO PHARMA GMBH (DE) | 2020-04-28 | — | — | US | claimed |
| US-20190177288-A1 | INTERMEDIATES AND PROCESS FOR PREPARING INTERMEDIATES IN THE PRODUCTION OF SUBSTITUTED PYRAZOLOPYRIDINES | ADVERIO PHARMA GMBH (DE) | 2019-06-13 | — | — | US | claimed |
| US-20180065942-A1 | CRYSTALLINE SUBSTITUTED 5-FLUORO-1H-PYRAZOLOPYRIDINES AND PROCESS FOR PREPARING | ADVERIO PHARMA GMBH (DE) | 2018-03-08 | — | — | US | claimed |
| US-9845300-B2 | Process for preparing substituted 5-fluoro-1H-pyrazolopyridines | ADVERIO PHARMA GMBH (DE) | 2017-12-19 | — | — | US | claimed |
| US-20170158652-A1 | PROCESS FOR PREPARING SUBSTITUTED 5-FLUORO-1H-PYRAZOLOPYRIDINES | ADVERIO PHARMA GMBH (DE) | 2017-06-08 | — | — | US | claimed |
| EP-2896617-B1 | METHOD FOR PRODUCING SUBSTITUTED (Z)-ALPHA-FLUORO-BETA-AMINO-ACRYLALDEHYDES | ADVERIO PHARMA GMBH (DE) | 2016-10-05 | — | — | EP | claimed |
| US-20160009671-A1 | PROCESS FOR PREPARING SUBSTITUTED 5-FLUORO-1H-PYRAZOLOPYRIDINES | ADVERIO PHARMA GMBH (DE) | 2016-01-14 | — | — | US | claimed |
| EP-2896617-A1 | Method for producing substituted 5-fluoro-1h-pyrazolopyridines | Adverio Pharma GmbH (DE) | 2015-07-22 | — | — | EP | claimed |
| US-20140315926-A1 | Process for preparing substituted 5-fluoro-1H-pyrazolopyridines | ADVERIO PHARMA GMBH (DE) | 2014-10-23 | — | — | US | claimed |
| EP-2782914-A1 | METHOD FOR PRODUCING SUBSTITUTED 5-FLUORO-1H-PYRAZOLOPYRIDINES | Bayer Pharma Aktiengesellschaft (DE) | 2014-10-01 | — | — | EP | claimed |
| US-20130143900-A1 | Process for preparing substituted 5-fluoro-1H-pyrazolopyridines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-06-06 | — | — | US | claimed |
| WO-2013076168-A1 | METHOD FOR PRODUCING SUBSTITUTED 5-FLUORO-1H-PYRAZOLOPYRIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2013-05-30 | — | — | WO | claimed |
| EP-4739675-A1 | INDOLE DERIVATIVES WITH FACTOR B INHIBITORY ACTIVITY | Sitala Bio Ltd (GB) | 2026-05-13 | — | — | EP | disclosed |
| EP-4739667-A2 | INDOLE DERIVATIVES WITH FACTOR B INHIBITORY ACTIVITY | Sitala Bio Ltd (GB) | 2026-05-13 | — | — | EP | disclosed |
| EP-3976604-B1 | 1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP (KR) | 2026-01-21 | — | — | EP | disclosed |
| US-12440484-B2 | 1,3,4-oxadiazole homophthalimide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | CHONG KUN DANG PHARMACEUTICAL CORPORATION (KR) | 2025-10-14 | — | — | US | disclosed |
| US-20050009838-A1 | Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors | PHARMACIA CORPORATION | 2005-01-13 | — | — | US | disclosed |
| US-20040138065-A1 | Malononitrile compounds and their use as pesticides | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2004-07-15 | — | — | US | disclosed |
| EP-1385817-A2 | MALONONITRILE COMPOUNDS AND THEIR USE AS PESTICIDES | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2004-02-04 | — | — | EP | disclosed |
| WO-2002090320-A2 | MALONONITRILE COMPOUNDS AND THEIR USE AS PESTICIDES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170158652-A1 | PROCESS FOR PREPARING SUBSTITUTED 5-FLUORO-1H-PYRAZOLOPYRIDINES | CYP3A5, CYP4F2, CYP2F1 | CA2 3178/4885CA1 4728/4885CA9 3916/4885 |
| US-20180065942-A1 | CRYSTALLINE SUBSTITUTED 5-FLUORO-1H-PYRAZOLOPYRIDINES AND PROCESS FOR PREPARING | CYP3A5, CYP2F1, CYP4F2 | CA2 1874/4885CA1 4077/4885CA9 3228/4885 |
| US-20160009671-A1 | PROCESS FOR PREPARING SUBSTITUTED 5-FLUORO-1H-PYRAZOLOPYRIDINES | CYP3A5, CYP4F2, CYP2F1 | CA2 3178/4885CA1 4728/4885CA9 3916/4885 |
| US-12440484-B2 | 1,3,4-oxadiazole homophthalimide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | HDAC1, HDAC11, HDAC3 | CA2 1703/4885CA1 1969/4885CA9 1509/4885 |
| US-20040138065-A1 | Malononitrile compounds and their use as pesticides | CBR1, MAL2, CBR3 | CA2 118/4885CA1 754/4885CA9 404/4885 |
| US-20050009838-A1 | Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors | MMP1, PREP, MMP3 | CA2 101/4885CA1 79/4885CA9 147/4885 |
| US-10633357-B2 | Intermediates and process for preparing intermediates in the production of substituted pyrazolopyridines | CYP3A5, CYP4F2, CYP2F1 | CA2 2527/4885CA1 4462/4885CA9 3623/4885 |
| US-20130143900-A1 | Process for preparing substituted 5-fluoro-1H-pyrazolopyridines | CYP3A5, CYP4F2, CYP2F1 | CA2 3178/4885CA1 4728/4885CA9 3916/4885 |
| US-20140315926-A1 | Process for preparing substituted 5-fluoro-1H-pyrazolopyridines | CYP3A5, CYP4F2, CYP2F1 | CA2 3178/4885CA1 4728/4885CA9 3916/4885 |
| US-20190177288-A1 | INTERMEDIATES AND PROCESS FOR PREPARING INTERMEDIATES IN THE PRODUCTION OF SUBSTITUTED PYRAZOLOPYRIDINES | CYP3A5, CYP4F2, CYP2F1 | CA2 2527/4885CA1 4462/4885CA9 3623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.